New hope for eczema patients who failed other treatments
NCT ID NCT06899204
Summary
This study is observing how well the oral medication abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) in real-world clinics. It focuses on about 150 patients aged 12 and older who did not get enough relief or could not tolerate up to two previous biologic injections. The main goal is to see how much the drug reduces skin symptoms and severe itching over 16 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGNew York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.